Zhiming Mao

Zhiming Mao

Auto-generated profile, based on publicly available information

Zhiming Mao

Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HHHyoungjun Ham
Hyoungjun Ham
JHJacob B. Hirdler
Jacob B. Hirdler
DBDaniel T. Bihnam
Daniel T. Bihnam
ZMZhiming Mao
Zhiming Mao
JGJoanina K. Gicobi
Joanina K. Gicobi
DBDaniel D. Billadeau
Daniel D. Billadeau
During infection and cancer, mTORC1-mediated metabolic regulation impacts CD8+ T cell effector expansion and memory development. However, the mechanisms by which CD8+ T cells regulate mTORC1 to support their unique metabolic requirements remain unknown. Here we show that NKG7, a lysosomal protein whose expression is restricted to cytotoxic lymphocytes, negatively regulates mTORC1 recruitment and activation by inhibiting assembly and function of the lysosomal proton pump, vacuolar ATPase (v-ATPase). Human and mouse CD8+ T cells lacking NKG7 show more acidic lysosomes and increased activation of mTORC1 signaling, which could be reversed by inhibition of v-ATPase activity. In mice responding to LCMV infection, NKG7-deleted effector CD8+ T cells are less durable and generate fewer memory precursors, whereas induced expression of NKG7 in CD8+ T cells results in increased presence of intra-tumoral T cells. Overall, our work identifies NKG7 as a CD8+ T cell-specific regulator of mTORC1 activity, required for optimal immune responses.

17 November 2023 in Science Advances
Verified
Journal Article
Open access
JGJoanina K. Gicobi
Joanina K. Gicobi
ZMZhiming Mao
Zhiming Mao
GDGrace DeFranco
Grace DeFranco
JHJacob B. Hirdler
Jacob B. Hirdler
YLYing Li
Ying Li
HDHaidong Dong
Haidong Dong
Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy to reduce tumor burden and tumor-related symptoms. Occasionally, some patients experience substantial global tumor regression with a rebound of cytotoxic CD8 + T cells. We have termed the rebound of cytotoxic CD8 + T cells in response to salvage therapy as T cell resilience and examined the underlying mechanisms of resilience. Resilient T cells are enriched for CX3CR1 + CD8 + T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8 + T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers. Thus, preserved resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency.

18 August 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
HDHaidong Dong
Haidong Dong
HHHyoungjun Ham
Hyoungjun Ham
WBWhitney Barham
Whitney Barham
TWTi Wen
Ti Wen
JHJacob B. Hirdler
Jacob B. Hirdler
DBDaniel D. Billadeau
Daniel D. Billadeau
The effectiveness of T cell–based immunotherapy depends on durable T-cell responses that can efficiently eliminate tumor cells. NKG7 was discovered three decades ago as a protein associated with lytic granules. However, only studies published over the past 5 years have contributed substantially to our understanding of NKG7 in T-cell biology. NKG7 has been recognized as an important T-cell functional marker in responses to immune checkpoint inhibitor therapy and in the prognosis of certain cancers. Besides its role in the generation, trafficking, and release of lytic granules, which is critical for efficient T-cell cytotoxicity against tumor cells, NKG7 has been identified as a key negative regulator of mTORC1 activity. By restraining mTORC1 activity, NKG7 promotes T-cell longevity and memory generation after infection. Importantly, NKG7 upregulation has demonstrated therapeutic potential in preclinical T-cell therapy for cancer. Collectively, NKG7 is emerging as a promising biomarker and therapeutic addition to T cell–based immunotherapies.

25 July 2014
Verified
Conference Paper
Closed access
Wei YanWei Yan
Wei Yan
JHJun Hu
Jun Hu
HZHuan Zhang
Huan Zhang
ZMZhiming Mao
Zhiming Mao
YCYIN Chao
YIN Chao
CZChenkai Zhang
Chenkai Zhang

18 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ZMZhiming Mao
Zhiming Mao
JHJacob B. Hirdler
Jacob B. Hirdler
JGJoanina K. Gicobi
Joanina K. Gicobi
MMMark Maynes
Mark Maynes
MHMichelle A. Hsu
Michelle A. Hsu
HDHaidong Dong
Haidong Dong
Durable T cell immunity against cancer depends on the continual replenishment of effector CD8+ T cells. Thymic output has been correlated with favorable prognosis in cancer patients across a range of ages, suggesting that the thymus is an important source for replenishing T cells capable of controlling cancer progression. However, the effector potential of thymic mature CD8+ T cells and their regulation have not been clearly defined. In this study, we identified the ability of thymic single positive CD8+ T cells to gain effector potential after thymic selection, but they are subject to the regulation of PD-1. We found a previously undisclosed role of PD-1 in limiting both the cytotoxic and exhaustion potential of thymic and peripheral CD8+ T cells. Our results show that although PD-1 inhibition facilitates the expansion of effector CD8+ T cells, effector CD8+ cells gradually lose their antitumor activity within tumor tissues due to advanced exhaustion in the absence of PD-1. Thus, although the preset effector potential in thymic mature CD8+ T cells allows them to rapidly respond to malignant cells in the periphery, PD-1, as a checkpoint, is embedded in the thymic mature CD8+ T cells after positive selection to balance their effector function from exaggeration and exhaustion. Therefore, we propose that a strategy capable of upholding the cytotoxic capacity and avoiding exhaustion of CD8+ T cells during the early stages of PD-1 inhibition therapy is needed to achieve durable antitumor immunity.

23 May 2026 in Nature Communications
Verified
Journal Article
Open access
ZMZhiming Mao
Zhiming Mao
JHJacob B. Hirdler
Jacob B. Hirdler
JGJoanina K. Gicobi
Joanina K. Gicobi
LDLi Ding
Li Ding
MMMark A. Maynes
Mark A. Maynes
HDHaidong Dong
Haidong Dong
Durable T cell immunity against cancer depends on the continual replenishment of effector CD8⁺ T cells. Thymic output has been associated with favorable prognosis in cancer patients across a range of ages, suggesting that the thymus is an important source for replenishing T cells capable of controlling cancer progression. However, whether CD8⁺ T cells acquire effector potential within the thymus, and how thymic output of effector CD8⁺ T cells contribute to peripheral tumor immunity, remain unclear. In this study, we discover that thymic single-positive (SP) CD8⁺ T cells undergo latent effector differentiation following thymic selection, but this process is subject to PD-1 regulation. We further demonstrate that PD-1 limits the contribution of thymic output of CD8⁺ T cells in shaping the TCR repertoire within the tumor tissues for tumor immunosurveillance. Although PD-1 inhibition facilitates the expansion of effector CD8⁺ T cells in the periphery, these cells gradually lose antitumor activity within tumors due to accelerated exhaustion in the absence of PD-1. Thus, while latent effector differentiation of thymic CD8⁺ T cells enables a rapid response to malignant cells in the periphery, PD-1 restrains this process to prevent overt or terminal effector differentiation, which may compromise balanced and durable peripheral immunity.